RESUMEN
Farnesyl:protein transferase (FPTase) inhibitors (FTIs) were originally developed as potential anticancer agents targeting the ras oncogene and are currently in clinical trials. Whereas FTIs inhibit the farnesylation of Ha-Ras, they do not completely inhibit the prenylation of Ki-Ras, the allele most frequently mutated in human cancers. Whereas farnesylation of Ki-Ras is blocked by FTIs, Ki-Ras remains prenylated in FTI-treated cells because of its modification by the related prenyltransferase, geranylgeranyl:protein transferase type I (GGPTase-I). Hence, cells transformed with Ki-ras tend to be more resistant to FTIs than Ha-ras-transformed cells. To determine whether Ki-ras-transformed cells can be targeted by combining an FTI with a GGPTase-I inhibitor (GGTI), we evaluated potent, selective FTIs, GGTIs, and dual prenylation inhibitors (DPIs) that have both FTI and GGTI activity. We find that in human PSN-1 pancreatic tumor cells, which harbor oncogenic Ki-ras, and in other tumor lines having either wild-type or oncogenic Ki-ras, treatment with an FTI/GGTI combination or with a DPI blocks Ki-Ras prenylation and induces markedly higher levels of apoptosis relative to FTI or GGTI alone. We demonstrate that these compounds can inhibit their enzyme targets in mice by monitoring pancreatic and tumor tissues from treated animals for inhibition of prenylation of Ki-Ras, HDJ2, a substrate specific for FPTase, and Rap1A, a substrate specific for GGPTase-I. Continuous infusion (72 h) of varying doses of GGTI in conjunction with a high, fixed dose of FTI causes a dose-dependent inhibition of Ki-Ras prenylation. However, a 72-h infusion of a GGTI, at a dose sufficient to inhibit Ki-Ras prenylation in the presence of an FTI, causes death within 2 weeks of the infusion when administered either as monotherapy or in combination with an FTI. DPIs are also lethal after a 72-h infusion at doses that inhibit Ki-Ras prenylation. Because 24 h infusion of a high dose of DPI is tolerated and inhibits Ki-Ras prenylation, we compared the antitumor efficacy from a 24-h FTI infusion to that of a DPI in a nude mouse/PSN-1 tumor cell xenograft model and in Ki-ras transgenic mice with mammary tumors. The FTI and DPI were dosed at a level that provided comparable inhibition of FPTase. The FTI and the DPI displayed comparable efficacy, causing a decrease in growth rate of the PSN-1 xenograft tumors and tumor regression in the transgenic model, but neither treatment regimen induced a statistically significant increase in tumor cell apoptosis. Although FTI/GGTI combinations elicit a greater apoptotic response than either agent alone in vitro, the toxicity associated with GGTI treatment in vivo limits the duration of treatment and, thus, may limit the therapeutic benefit that might be gained by inhibiting oncogenic Ki-Ras through dual prenyltransferase inhibitor therapy.
Asunto(s)
Transferasas Alquil y Aril/antagonistas & inhibidores , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Inhibidores Enzimáticos/farmacología , Transferasas Alquil y Aril/metabolismo , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/toxicidad , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Ensayos de Selección de Medicamentos Antitumorales , Sinergismo Farmacológico , Inhibidores Enzimáticos/administración & dosificación , Inhibidores Enzimáticos/toxicidad , Farnesiltransferasa , Femenino , Humanos , Ratones , Ratones Desnudos , Neoplasias Pancreáticas/tratamiento farmacológico , Neoplasias Pancreáticas/enzimología , Neoplasias Pancreáticas/patología , Prenilación de Proteína/efectos de los fármacos , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto , Proteínas ras/metabolismoRESUMEN
Macrophages secrete matrix metalloproteinase 9 (MMP-9), an enzyme that weakens the fibrous cap of atherosclerotic plaques, predisposing them to plaque rupture and subsequent ischemic events. Recent work indicates that statins strongly reduce the possibility of heart attack. Furthermore, these compounds appear to exert beneficial effects not only by lowering plasma low-density-lipoprotein cholesterol but also by directly affecting the artery wall. To evaluate whether statins influence the proinflammatory responses of monocytic cells, we studied their effects on the chemotactic migration and MMP-9 secretion of human monocytic cell line THP-1. Simvastatin dose dependently inhibited THP-1 cell migration mediated by monocyte chemoattractant protein 1, with a 50% inhibitory concentration of about 50 nM. It also inhibited bacterial lipopolysaccharide-stimulated secretion of MMP-9. The effects of simvastatin were completely reversed by mevalonate and its derivatives, farnesylpyrophosphate and geranylgeranyl pyrophosphate, but not by ubiquinone. Additional studies revealed similar but more profound inhibitory effects with L-839,867, a specific inhibitor of geranylgeranyl transferase. However, alpha-hydroxyfarnesyl phosphonic acid, an inhibitor of farnesyl transferase, had no effect. C3 exoenzyme, a specific inhibitor of the prenylated small signaling Rho proteins, mimicked the inhibitory effects of simvastatin and L-839,867. These data supported the role of geranylgeranylation in the migration and MMP-9 secretion of monocytes.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Toxinas Botulínicas , Quimiotaxis/efectos de los fármacos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Metaloproteinasa 9 de la Matriz/metabolismo , Monocitos/efectos de los fármacos , Compuestos Orgánicos , Prenilación de Proteína/efectos de los fármacos , Procesamiento Proteico-Postraduccional/efectos de los fármacos , Simvastatina/farmacología , ADP Ribosa Transferasas/farmacología , Transferasas Alquil y Aril/antagonistas & inhibidores , Movimiento Celular/efectos de los fármacos , Quimiocina CCL2/farmacología , Depresión Química , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Leucemia Monocítica Aguda/patología , Lipopolisacáridos/farmacología , Ácido Mevalónico/farmacología , Monocitos/enzimología , Monocitos/metabolismo , Proteínas de Neoplasias/antagonistas & inhibidores , Proteínas de Neoplasias/metabolismo , Fosfatos de Poliisoprenilo/farmacología , Sesquiterpenos , Simvastatina/antagonistas & inhibidores , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
A series of 2-arylindole-3-acetamide farnesyl protein transferase inhibitors has been identified. The compounds inhibit the enzyme in a farnesyl pyrophosphate-competitive manner and are selective for farnesyl protein transferase over the related enzyme geranylgeranyltransferase-I. A representative member of this series of inhibitors demonstrates equal effectiveness against HDJ-2 and K-Ras farnesylation in a cell-based assay when geranylgeranylation is suppressed.
Asunto(s)
Transferasas Alquil y Aril/antagonistas & inhibidores , Ácidos Indolacéticos/metabolismo , Ácidos Indolacéticos/farmacología , Prenilación de Proteína/efectos de los fármacos , Proteínas ras/metabolismo , Transferasas Alquil y Aril/metabolismo , Proteínas Portadoras/metabolismo , Inhibidores Enzimáticos/síntesis química , Inhibidores Enzimáticos/metabolismo , Inhibidores Enzimáticos/farmacología , Proteínas del Choque Térmico HSP40 , Proteínas de Choque Térmico/metabolismo , Humanos , Ácidos Indolacéticos/síntesis química , Prenilación de Proteína/fisiología , Relación Estructura-Actividad , Células Tumorales CultivadasRESUMEN
We have identified and characterized potent and specific inhibitors of geranylgeranyl-protein transferase type I (GGPTase I), as well as dual inhibitors of GGPTase I and farnesyl-protein transferase. Many of these inhibitors require the presence of phosphate anions for maximum activity against GGPTase I in vitro. Inhibitors with a strong anion dependence were competitive with geranylgeranyl pyrophosphate (GGPP), rather than with the peptide substrate, which had served as the original template for inhibitor design. One of the most effective anions was ATP, which at low millimolar concentrations increased the potency of GGPTase I inhibitors up to several hundred-fold. In the case of clinical candidate l-778,123, this increase in potency was shown to result from two major interactions: competitive binding of inhibitor and GGPP, and competitive binding of ATP and GGPP. At 5 mm, ATP caused an increase in the apparent K(d) for the GGPP-GGPTase I interaction from 20 pm to 4 nm, resulting in correspondingly tighter inhibitor binding. A subset of very potent GGPP-competitive inhibitors displayed slow tight binding to GGPTase I with apparent on and off rates on the order of 10(6) m(-)1 s(-)1 and 10(-)3 s(-)1, respectively. Slow binding and the anion requirement suggest that these inhibitors may act as transition state analogs. After accounting for anion requirement, slow binding, and mechanism of competition, the structure-activity relationship determined in vitro correlated well with the inhibition of processing of GGPTase I substrate Rap1a in vivo.
Asunto(s)
Transferasas Alquil y Aril/antagonistas & inhibidores , Aniones/metabolismo , Inhibidores Enzimáticos/farmacología , Adenosina Trifosfato/metabolismo , Unión Competitiva , Humanos , Imidazoles/farmacología , Cinética , Modelos Químicos , Fosfatos de Poliisoprenilo/metabolismo , Unión Proteica , Relación Estructura-ActividadRESUMEN
As part of an ongoing effort to prepare therapeutically useful orally active thrombin inhibitors, we have synthesized a series of compounds that utilize nonbasic groups in the P1 position. The work is based on our previously reported lead structure, compound 1, which was discovered via a resin-based approach to varying P1. By minimizing the size and lipophilicity of the P3 group and by incorporating hydrogen-bonding groups on the N-terminus or on the 2-position of the P1 aromatic ring, we have prepared a number of derivatives in this series that exhibit subnanomolar enzyme potency combined with good in vivo antithrombotic and bioavailability profiles. The oxyacetic amide compound 14b exhibited the best overall profile of in vitro and in vivo activity, and crystallographic studies indicate a unique mode of binding in the thrombin active site.
Asunto(s)
Ciclohexilaminas/síntesis química , Dipéptidos/síntesis química , Fibrinolíticos/síntesis química , Trombina/antagonistas & inhibidores , Administración Oral , Animales , Sitios de Unión , Disponibilidad Biológica , Simulación por Computador , Cristalografía por Rayos X , Ciclohexilaminas/química , Ciclohexilaminas/farmacocinética , Dipéptidos/química , Dipéptidos/farmacocinética , Perros , Diseño de Fármacos , Fibrinolíticos/química , Fibrinolíticos/farmacocinética , Fibrinolíticos/farmacología , Enlace de Hidrógeno , Macaca fascicularis , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Ratas , Resinas de Plantas , Relación Estructura-Actividad , Trombina/químicaRESUMEN
Study of surface representations of the inhibitor-bound thrombin P-1 pocket revealed a lipophilic recess in this pocket which is not occupied by any known inhibitor. Solid-phase synthesis was used to generate benzylamides of D-diphenylAlaPro by aminolysis of Boc dipeptide Kaiser resin. The resulting amides inhibited thrombin in the range IC50 = 3-13,000 nM, and the structure-activity relationships and molecular modeling suggest a unique fit of the benzyl side chain into P-1 with the meta substituent occupying the recess.
Asunto(s)
Antitrombinas/síntesis química , Compuestos de Bencidrilo/síntesis química , Pirroles/síntesis química , Trombina/antagonistas & inhibidores , Antitrombinas/química , Compuestos de Bencidrilo/química , Diseño de Fármacos , Modelos Moleculares , Pirroles/química , Relación Estructura-ActividadRESUMEN
Early studies in these laboratories of peptidomimetic structures containing a basic P1 moiety led to the highly potent and selective thrombin inhibitors 2 (Ki = 5.0 nM) and 3 (Ki = 0.1 nM). However, neither attains significant blood levels upon oral administration to rats and dogs. With the aim of improving pharmacokinetic properties via a more diverse database, we devised a resin-based route for the synthesis of analogues of these structures in which the P3 residue is replaced with a range of lipophilic carboxylic amides. Assembly proceeds from the common P2-P1 template 7 linked via an acid-labile carbamate to a polystyrene support. Application of the methodology in a repetitive fashion afforded several interesting analogues out of a collection of some 200 compounds. Among the most potent of the group, N-(9-hydroxy-9-fluorenecarboxy)-prolyl trans-4-aminocyclohexylmethyl amide (L-372,460 8, Ki = 1.5 nM), in addition to being fully efficacious in a rat model of arterial thrombosis at an infusion rate of 10 micrograms/kg/min, exhibits oral bioavailability of 74% in dogs, and oral bioavailability of 39% in monkeys with a serum half-life of just under 4 h. On the basis of its favorable biological properties, inhibitor 8 has been subject to further evaluation as a possible treatment for thrombogenic disorders.
Asunto(s)
Antitrombinas/química , Diseño de Fármacos , Pirrolidinas/química , Animales , Antitrombinas/farmacocinética , Antitrombinas/farmacología , Disponibilidad Biológica , Perros , Haplorrinos , Modelos Moleculares , Pirrolidinas/farmacocinética , Pirrolidinas/farmacología , Ratas , Relación Estructura-ActividadRESUMEN
As part of an effort to prepare efficacious and orally bioavailable analogs of the previously reported thrombin inhibitors 1a, b, we have synthesized a series of compounds that utilize 3,3-disubstituted propionic acid derivatives as P3 ligands. By removing the N-terminal amino group, the general oral bioavailability of this class of compounds was enhanced without excessively increasing the lipophilicity of the compounds. The overall properties of the molecules could be drastically altered depending on the nature of the groups substituted onto the 3-position of the P3 propionic acid moiety. A number of the compounds exhibited good oral bioavailability in rats and dogs, and numerous compounds were efficacious in a rat FeCl3-induced model of arterial thrombosis. Compound 7, the 3,3-diphenylpropionic acid derivative, showed the best overall profile of in vivo and in vitro activity. Molecular modeling studies suggest that these compounds bind in the thrombin active site in a manner essentially identical to that previously reported for compound 1a.
Asunto(s)
Propionatos/síntesis química , Trombina/antagonistas & inhibidores , Administración Oral , Animales , Disponibilidad Biológica , Perros , Espectroscopía de Resonancia Magnética , Propionatos/farmacocinética , Propionatos/farmacología , Ratas , Espectrometría de Masa Bombardeada por Átomos VelocesRESUMEN
In an effort to prepare orally bioavailable analogs of our previously reported thrombin inhibitor 1, we have synthesized a series of compounds that utilize the unique amino acid D-dicyclohexylalanine as a P3 ligand. The resulting compounds are extremely potent and selective thrombin inhibitors, and the N-terminal Boc derivative 8 exhibited excellent oral bioavailability and pharmacokinetics in both rats and dogs. The des-Boc analog 6 was not orally bioavailable in rats. The high level of oral bioavailability observed with 8 appears to be a direct function of its increased lipophilicity versus other close analogs. Although increased lipophilicity may serve to increase the oral absorption of tripeptide thrombin inhibitors, it also appears to have detrimental effects on the antithrombotic properties observed with the compounds. Compound 6 performed extremely well in our in vivo antithrombotic assay, while the much more lipophilic but essentially equipotent analog 8 performed poorly. We have found that in general with this series of thrombin inhibitors as well as with other unreported series, increased lipophilicity and the associated increases in plasma protein binding have detrimental effects on 2X APTT values and subsequent performance in in vivo antithrombotic models.
Asunto(s)
Dipéptidos/síntesis química , Fibrinolíticos/síntesis química , Fenilalanina/análogos & derivados , Trombina/antagonistas & inhibidores , Animales , Disponibilidad Biológica , Dipéptidos/farmacocinética , Dipéptidos/uso terapéutico , Perros , Fibrinolíticos/farmacocinética , Fibrinolíticos/uso terapéutico , Metabolismo de los Lípidos , Masculino , Estructura Molecular , Tiempo de Tromboplastina Parcial , Fenilalanina/química , Ratas , Ratas Sprague-Dawley , Relación Estructura-Actividad , Trombosis/tratamiento farmacológicoAsunto(s)
Dipéptidos/química , Diseño de Fármacos , Fibrinolíticos/química , Trombina/antagonistas & inhibidores , Sitios de Unión , Cristalografía por Rayos X , Ciclohexilaminas/síntesis química , Ciclohexilaminas/química , Ciclohexilaminas/metabolismo , Ciclohexilaminas/farmacología , Dipéptidos/síntesis química , Dipéptidos/metabolismo , Dipéptidos/farmacología , Fibrinolíticos/síntesis química , Fibrinolíticos/metabolismo , Fibrinolíticos/farmacología , Enlace de Hidrógeno , Estructura Molecular , Unión Proteica , Trombina/química , Trombina/metabolismoAsunto(s)
Fármacos Anti-VIH/síntesis química , Transcriptasa Inversa del VIH/antagonistas & inhibidores , Transcriptasa Inversa del VIH/química , Inhibidores de la Transcriptasa Inversa/síntesis química , Fármacos Anti-VIH/química , Fármacos Anti-VIH/farmacología , Línea Celular , Supervivencia Celular/efectos de los fármacos , Diseño de Fármacos , Infecciones por VIH/tratamiento farmacológico , VIH-1/efectos de los fármacos , VIH-1/enzimología , Humanos , Modelos Moleculares , Conformación Molecular , Estructura Molecular , Nevirapina , Conformación Proteica , Piridinas/química , Piridinas/farmacología , Inhibidores de la Transcriptasa Inversa/química , Inhibidores de la Transcriptasa Inversa/farmacología , Relación Estructura-ActividadRESUMEN
The clinical benefit of the human immunodeficiency virus type 1 (HIV-1) nonnucleoside reverse transcriptase (RT) inhibitors (NNRTIs) is limited by the rapid selection of inhibitor-resistant viral variants. However, it may be possible to enhance the clinical utility of this inhibitor class by deriving compounds that express both high levels of antiviral activity and an augmented pharmacokinetic profile. Accordingly, we developed a new class of NNRTIs, the 1, 4-dihydro-2H-3, 1-benzoxazin-2-ones. L-743, 726 (DMP-266), a member of this class, was chosen for clinical evaluation because of its in vitro properties. The compound was a potent inhibitor of the wild-type HIV-1 RT (Ki = 2.93 nM) and exhibited a 95% inhibitory concentration of 1.5 nM for the inhibition of HIV-1 replicative spread in cell culture. In addition, L-7743, 7726 was found to be capable of inhibiting, with 95% inhibitory concentrations of < or = 1.5 microM, a panel of NNRTI-resistant mutant viruses, each of which expressed a single RT amino acid substitution. Derivation of virus with notably reduced susceptibility to the inhibitor required prolonged cell culture selection and was mediated by a combination of at least two RT amino acid substitutions. Studies of L-743, 726 in rats, monkeys, and a chimpanzee demonstrated the compound's potential for good oral bioavailability and pharmacokinetics in humans.
Asunto(s)
Antivirales/farmacología , VIH-1/enzimología , Oxazinas/farmacología , ADN Polimerasa Dirigida por ARN/metabolismo , Inhibidores de la Transcriptasa Inversa/farmacología , Alquinos , Animales , Antivirales/farmacocinética , Benzoxazinas , Disponibilidad Biológica , Línea Celular , Cristalografía por Rayos X , Ciclopropanos , Farmacorresistencia Microbiana , Transcriptasa Inversa del VIH , VIH-1/efectos de los fármacos , Semivida , Humanos , Macaca mulatta , Masculino , Estructura Molecular , Oxazinas/farmacocinética , Pan troglodytes , Ratas , Ratas Sprague-Dawley , Inhibidores de la Transcriptasa Inversa/farmacocinética , Linfocitos T/virologíaRESUMEN
As part of an ongoing effort to prepare novel non-nucleoside inhibitors of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT), a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin -2(1H)-ones 4aa-l has been prepared. Target compounds 4a-e were synthesized via addition of various 1-lithio-2-(aryl)alkyne nucleophiles to a 1-protected-4-cyclopropylquinazolin-2(1H)-one (7), followed by deprotection. The 3-methyl compound 4aa was prepared in an analogous manner, with the 3-alkylation performed prior to deprotection. Alternatively, the target compounds 4f-l were prepared by addition of 1-lithio-2-(trimethylsilyl)acetylene to 7, followed by deprotection and subsequent palladium-catalyzed coupling with various aryl halides. By incorporating an aryl group onto the end of the 4-acetylene functionality, the requirement for a metabolically labile 3-methyl group on the dihydroquinazolinone nucleus has been eliminated. A number of the target compounds were shown to be potent inhibitors of HIV-1 RT. Compound 4a, which had exhibited the most favorable overall biological profile, was resolved via a four-step procedure to provide the enantiomers 13a and 13b. Compound 13a having the (-)-4(S) configuration was shown to be the active enantiomer and was selected as a candidate for further investigation.
Asunto(s)
VIH-1/enzimología , Quinazolinas/farmacología , Inhibidores de la Transcriptasa Inversa , Células Cultivadas , Cristalografía por Rayos X , Transcriptasa Inversa del VIH , Humanos , Quinazolinas/síntesis químicaRESUMEN
A series of HIV-1 protease inhibitors containing a novel hydroxyethyl secondary amine transition state isostere has been synthesized. The compounds exhibit a strong preference for the (R) stereochemistry at the transition state hydroxyl group. Molecular modeling studies with the prototype compound 11 have provided important insights into the structural requirements for good inhibitor-active site binding interaction. N-Terminal extension of 11 into the P2-P3 region led to the discovery of 19, the most potent enzyme inhibitor in the series (IC50 = 5.4 nM). 19 was shown to have potent antiviral activity in cultured MT-4 human T-lymphoid cells. Comparison of analogs of 19 with analogs of 1 (Ro31-8959) demonstrates that considerably different structure-activity relationships exist between these two subclasses of hydroxyethylamine HIV-protease inhibitors.
Asunto(s)
Antivirales/síntesis química , Etilaminas/farmacología , Inhibidores de la Proteasa del VIH , VIH-1/enzimología , Inhibidores de Proteasas/síntesis química , Secuencia de Aminoácidos , Antivirales/farmacología , Sitios de Unión , Células Cultivadas , Ensayo de Inmunoadsorción Enzimática , Etilaminas/química , Proteína p24 del Núcleo del VIH/análisis , Proteasa del VIH/metabolismo , Humanos , Espectrometría de Masas , Modelos Moleculares , Datos de Secuencia Molecular , Inhibidores de Proteasas/farmacologíaRESUMEN
A series of novel arylpiperazines have been prepared in an attempt to incorporate both class II (beta-receptor blocking) and class III antiarrhythmic properties in a single molecule. The key step in the preparation of the new compounds involves a regioselective heterocyclic ring formation. All but four compounds significantly prolonged action potential duration in canine cardiac Purkinje fibers (class III activity). All but one of the compounds demonstrated beta-receptor affinity in a competitive binding assay and three had beta 1-receptor selectivity. Compared to sotalol, a reference class II/III agent, arylpiperazine 7a (4-[(methylsulfonyl)amino]-N-[(4- phenylpiperazin-2-yl)methyl]benzamide) demonstrated beta 1-selectivity and was 1 order of magnitude more potent in the in vitro class III and the beta 1-receptor screens. Compound 7a was evaluated further and found to be effective in preventing programmed electrical stimulation-induced arrhythmias in conscious dogs (class III activity) and against epinephrine-induced arrhythmias in halothane anesthetized dogs (class II activity).
Asunto(s)
Antagonistas Adrenérgicos beta/síntesis química , Antiarrítmicos/síntesis química , Benzamidas/síntesis química , Corazón/fisiología , Piperazinas/síntesis química , Potenciales de Acción/efectos de los fármacos , Antagonistas Adrenérgicos beta/farmacología , Antagonistas Adrenérgicos beta/uso terapéutico , Animales , Antiarrítmicos/farmacología , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/tratamiento farmacológico , Arritmias Cardíacas/etiología , Benzamidas/farmacología , Benzamidas/uso terapéutico , Unión Competitiva , Perros , Estimulación Eléctrica , Electrofisiología , Epinefrina , Corazón/efectos de los fármacos , Estructura Molecular , Piperazinas/farmacología , Piperazinas/uso terapéutico , Ramos Subendocárdicos/efectos de los fármacos , Ramos Subendocárdicos/fisiología , Receptores Adrenérgicos beta/metabolismo , Sotalol/farmacología , Sotalol/uso terapéutico , Relación Estructura-ActividadRESUMEN
The oxygen-derived free radical superoxide anion (.O2-) plays an important role in the pathogenesis of various diseases. Recent demonstrations that .O2- inactivates the potent vasodilator endothelium-derived relaxing factor (EDRF) and that EDRF is probably nitric oxide (NO) suggest that EDRF(NO) may act as an endogenous free radical scavenger. This hypothesis was tested in an in vitro system by analyzing the effect of authentic NO (dilutions of a saturated aqueous solution) on .O2- production (detected spectrophotometrically as reduction of cytochrome c) by fMet-Leu-Phe-activated human leukocytes (PMN). NO depressed the rate of reduction of cytochrome c by .O2- released from PMN's or generated from the oxidation of hypoxanthine by xanthine oxidase. This effect was concentration-dependent and occurred at dilutions of the saturated NO solution (1:250 to 1:10) which inhibited platelet aggregation. NO had no direct effect on cytochrome c or on xanthine oxidase. These observations indicate that NO(EDRF) can be regarded as a scavenger of superoxide anion and they suggest that EDRF(NO) may provide a chemical barrier to cytotoxic free radicals (.O2-).
Asunto(s)
Neutrófilos/fisiología , Óxido Nítrico/farmacología , Agregación Plaquetaria/efectos de los fármacos , Superóxidos/sangre , Adenosina Difosfato/farmacología , Citocalasina B/farmacología , Grupo Citocromo c/metabolismo , Humanos , Técnicas In Vitro , Cinética , N-Formilmetionina Leucil-Fenilalanina/farmacología , Neutrófilos/efectos de los fármacos , Xantina Oxidasa/metabolismoRESUMEN
The dipeptide mimic Val psi[CH(CONH2)NH]His (4) was incorporated into angiotensin II (AII) analogues to provide an octapeptide saralasin derivative (29) as well as tetrapeptide analogue 19. Three C-terminal tetrapeptides (21, 25, and 28) were also prepared. All compounds were tested for their ability to displace 3H-AII from rabbit adrenal gland homogenate and as antagonists of AII and AI on guinea pig ileum. The octapeptide analogue 29 was 700 times less active than the parent peptide 30. All the C-terminal fragments 19, 21, 25, and 28 have no measurable AII antagonist activity. Of the four tetrapeptide fragments, only 21 showed any appreciable binding activity.
Asunto(s)
1-Sarcosina-8-Isoleucina Angiotensina II/análogos & derivados , Angiotensina II/análogos & derivados , Dipéptidos , Oligopéptidos/síntesis química , Glándulas Suprarrenales/metabolismo , Secuencia de Aminoácidos , Angiotensina I/antagonistas & inhibidores , Angiotensina II/antagonistas & inhibidores , Angiotensina II/metabolismo , Antagonistas de Receptores de Angiotensina , Animales , Fenómenos Químicos , Química Física , Cobayas , Íleon/fisiología , Datos de Secuencia Molecular , Contracción Muscular/efectos de los fármacos , Oligopéptidos/química , Oligopéptidos/farmacología , Fragmentos de Péptidos/síntesis química , Fragmentos de Péptidos/farmacología , Conejos , Receptores de Angiotensina/metabolismo , Saralasina/análogos & derivados , Saralasina/química , Saralasina/farmacologíaRESUMEN
Twenty-six alkyl and aralkyl histamine analogues were prepared as potential cardiotonic agents. Compounds were designed to allow interaction with a putative secondary aryl binding site at the H2 receptor, the presence of which was inferred from the structure of cyprohepatadine, which is known to have H2-antagonist properties. The compounds were examined for inotropic activity in ferret papillary muscle. Potent inotropic activity was generally found in N-alkyl- and N,N-dialkylimidazole-4-ethanamines, whereas N-(amidoalkyl)imidazole-4-ethanamines and N-alkylimidazole-4-propanamines were at best weakly active. Five compounds were examined in screens designed to assess hemodynamic effects and gastric acid secretion in vivo. Two of these compounds, alpha-(3-phenyl-2-transpropenyl)-1H-imidazole-4-ethanamine and N-heptyl-1H-imidazole-4-ethanamine, showed positive inotropic activity with minimal effects on heart rate and mean arterial pressure in vivo; however, both compounds were found to stimulate gastric acid secretion. These results demonstrate that selectivity between various H2-receptor-mediated activities can be obtained with substituted histamine analogues.
Asunto(s)
Cardiotónicos/síntesis química , Diseño de Fármacos , Ácido Gástrico/metabolismo , Histamina/análogos & derivados , Receptores Histamínicos H2/efectos de los fármacos , Animales , Cardiotónicos/farmacología , Hurones , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Contracción Miocárdica/efectos de los fármacos , RatasAsunto(s)
Antiarrítmicos/síntesis química , Imidazoles/síntesis química , Propanolaminas/síntesis química , Sulfonamidas/síntesis química , Animales , Fenómenos Químicos , Química , Perros , Electrofisiología , Hemodinámica/efectos de los fármacos , Imidazoles/farmacología , Propanolaminas/farmacología , Ramos Subendocárdicos/efectos de los fármacos , Ramos Subendocárdicos/fisiología , Relación Estructura-Actividad , Sulfonamidas/farmacologíaRESUMEN
The synthesis and cardiac electrophysiological activity of 18 N-substituted imidazolylbenzamides or benzene-sulfonamides are described. Compounds 6a,d,f-k and 11 exhibited potency in the in vitro Purkinje fiber assay comparable to that of N-[2-(diethylamino)ethyl]-4- [(methylsulfonyl)amino]benzamide (1, sematilide), a potent selective class III agent which is undergoing clinical trials. These data indicate that the 1H-imidazol-1-yl moiety is a viable replacement for the methylsulfonylamino group for producing class III electrophysiological activity in the N-substituted benzamide series. N-[2-(Diethylamino)ethyl]-4-(1H-imidazol-1-yl)benzamide dihydrochloride (6a) was further studied in two in vivo models of reentrant arrhythmias and showed potency and efficacy comparable to those of 1.